| Document |
Document Title |
|
WO/2023/100977A1 |
The present invention addresses the problem of revealing a symptom onset mechanism of allergies in which bacteria belonging to the family Lachnospiraceae including Ruminococcus gnavus (R. gnavus) which is an enteric bacterium is involved...
|
|
WO/2023/100134A1 |
This disclosure relates to combination therapies for use in treating cancer, comprising a CDK2 inhibitor of Formula (I) and a selective CDK4 inhibitor of Formula (II), each as further described herein, optionally in further combination w...
|
|
WO/2023/100131A1 |
The disclosure provides methods of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of PF-07104091, as a monotherapy or in combination with an endocrine therapy agent...
|
|
WO/2023/100829A1 |
The present invention provides a novel MuSK antibody. The present invention provides a molecule which binds to a target antigen, and is characterized by comprising a region that binds to the target antigen, a first peptide that recogni...
|
|
WO/2023/102018A1 |
The present disclosure provides compositions, systems, pre-filled delivery devices, and methods for developing injectable compositions useful for in situ forming solid depots for the sustained release of non-steroidal anti-inflammatory d...
|
|
WO/2023/100070A1 |
The disclosure provides a method of treating cancer comprising administering to a subject in need thereof with a therapeutically effective amount of PF-07220060. The disclosure also provides a method of treating cancer comprising adminis...
|
|
WO/2023/095929A1 |
Provided are: an agent for treatment of malignant tumors, the agent being characterized by containing an immune checkpoint inhibitor and by being used in combination with a boron neutron capture therapy; (i) an immune checkpoint inhibito...
|
|
WO/2023/092988A1 |
An application of a trihalophenol inhibitor in preparation of a drug for regulating and controlling the anti-infection capability of macrophages. Trihalophenol DBPs can cause damage of anti-infection immunity of mammals by interfering wi...
|
|
WO/2023/094580A1 |
The present invention relates to an oral anti-ageing composition comprising a mixture of: - At least one ingredient chosen from the group of niacinamide mononucleotide (NMN), niacinamide riboside (NR) and niacin - Resveratrol and/or pter...
|
|
WO/2023/093763A1 |
Provided are systems and methods for immunotherapies. Immune cells can be engineered to exhibit enhanced half-life as compared to control cell (e.g., a non-engineered immune cell). Immune cells can be engineered to exhibit enhanced proli...
|
|
WO/2023/096448A1 |
The present invention relates to a use of Obatoclax in treating metabolic and fibrotic diseases, and more specifically, to a novel use of Obatoclax in preventing or treating metabolic and fibrotic diseases, wherein Obatoclax exhibits the...
|
|
WO/2023/093840A1 |
This disclosure relates to the use of Wee1 kinase inhibitors in the treatment of cancer. In particular, the disclosure provides the use of Wee1 kinase inhibitors in the preparation of drugs for the treatment of cancers with FBXW7 or CHD4...
|
|
WO/2023/093807A1 |
The present invention relates to a compound and method for treating liver diseases.
|
|
WO/2023/095860A1 |
The present invention provides a medicine useful for treating and/or preventing COVID-19. Provided is a medicine characterized by combining: (A) a compound represented by formula (I) (where: Y is N; R1 represents an optionally substitute...
|
|
WO/2023/091901A1 |
Described herein are methods and compositions for treating or reducing the likelihood of a subject developing a pancreatic disease or disorder or keloids. In one embodiment, the method comprises administering a therapeutically effective ...
|
|
WO/2023/088464A1 |
The present invention relates to the field of biomedicine, and particularly relates to a CD300LD inhibitor and a use thereof in preparation of a tumor immunotherapy product. According to the present invention, the CD300LD inhibitor adjus...
|
|
WO/2023/090425A1 |
The present invention addresses the problem of providing an anti-inflammation agent for intraocular applications, which can prevent an excessive inflammation in an interocular tissue. The anti-inflammation agent comprises an ERK-activati...
|
|
WO/2023/088356A1 |
An application of a receptor-interacting protein 2 (RIP2) inhibitor combined with a chemotherapy drug, particularly, an application of a RIP2 inhibitor combined with a chemotherapy drug in preparation of a drug for treating and/or preven...
|
|
WO/2023/087421A1 |
Provided is the use of polymerized hemoglobin in the preparation of a drug for treating an ischemic stroke. The drug is a hemoglobin oxygen carrier and is also a colloid solution, and the particle size of the polymerized hemoglobin is on...
|
|
WO/2023/090728A1 |
The present invention relates to a compound for inhibiting tankyrase, and medical use thereof. Since the compound according to the present invention inhibits the activity of enzyme tankyrase (TNKS), inhibits target β-catenin gene expres...
|
|
WO/2023/091625A1 |
Characterization of drug-drug interaction properties and pharmacological properties of maribavir is useful to inform potential drug-drug interactions and dosing strategies when administering with co-medications.
|
|
WO/2023/088415A1 |
An Andrias davidianus skin secretion hydrolysate, and a preparation method therefor and an application thereof The preparation method comprises: S1: mixing a disulfide bond reducing agent and a first solvent to obtain a second solvent; S...
|
|
WO/2023/088235A1 |
The present disclosure relates to the biopharmaceutical field, in particular, Exatecan derivatives, linker-payloads, and conjugates and thereof antibody-drug conjugates, and the corresponding preparing process and use thereof.
|
|
WO/2023/090662A1 |
In the present invention, calsequestrin 1 (CASQ1) binds to STIM2 through the C1 (N-terminal 92 amino acid sequence) site of CASQ1 and the expression of CASQ1 or the C1 site thereof (CASQ1-STIM2 binding) is identified to lower store-opera...
|
|
WO/2023/089132A1 |
The present invention relates to aqueous pharmaceutical formulations, methods for their production, and uses thereof. The aqueous pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound and wa...
|
|
WO/2023/089032A1 |
The invention relates to methods and pharmaceutical compositions for the treatment of cancer, particularly BRCA-associated cancer and chemo-resistance BRCA-associated cancer. The inventors investigated the role of NMNAT1 in cancer, parti...
|
|
WO/2023/090850A1 |
The present invention provides a pharmaceutical composition for preventing or treating a cancer, which comprises a combination of a first compartment comprising a derivative having a certain cyclohexyl-ethylene-amino-heteroaryl moiety or...
|
|
WO/2023/092046A1 |
Disclosed herein is a method for treating and/or minimize injection site reactions (ISRs) and/or preventing severe ISRs in a subject in need thereof by admixing, co-formulating or co-administering a steroid composition. In some embodimen...
|
|
WO/2023/092112A1 |
The present disclosure provides methods of treating a subject having a headache or a migraine or preventing a subject from developing a headache or a migraine by administering an Sodium Voltage-Gated Channel Alpha Subunit 11 (SCN11A) inh...
|
|
WO/2023/090903A1 |
The present application relates to a composition which is for preventing or treating cancer or inflammation and comprises a novel Leuconostoc mesenteroides strain, a culture thereof, or an ingredient derived therefrom.
|
|
WO/2023/091905A1 |
Disclosed herein are targeted extracellular vesicles (e.g., exosomes, ectosomes, microvesicles/microparticles, apoptotic bodies, macrovesicles) and targeted micelles, as well as methods of using a targeted extracellular vesicle or a targ...
|
|
WO/2023/091553A1 |
The disclosure provides an effective amount of lasofoxifene, or a pharmaceutically acceptable salt or functional derivative thereof, for use in methods for treating estrogen receptor positive (ER+) cancer in a patient who has progressed ...
|
|
WO/2023/091990A1 |
The present disclosure provides compounds that block and/or disrupt GABA signaling. The disclosed compounds can decrease and/or inhibit activity, function, expression, and/or accumulation of GAD1, GABABR, and/or GABA and can be used in c...
|
|
WO/2023/090391A1 |
The purpose of the present disclosure is to provide: a method for testing for the presence/absence of hypertension, and the severity or prognosis thereof; a pathological animal model for pulmonary arterial hypertension (PAH); and a preve...
|
|
WO/2023/090409A1 |
In one embodiment, the present invention pertains to a peptide having affinity for the human transferrin receptor, and to applications of the same, wherein in order to pass through the blood-brain barrier, the peptide can be used by bind...
|
|
WO/2023/091746A1 |
The present disclosure relates to methods of treating cancer by administering a compound, which is a Fibroblast Growth Factor Receptor (FGFR) inhibitor, in combination with a Kirsten rat sarcoma (KRAS) inhibitor.
|
|
WO/2023/089612A1 |
The invention generally concerns peripherally restricted CB1 antagonists for treatment of LUTS.
|
|
WO/2023/090381A1 |
Disclosed is a new anti-HBV agent targeting host factor DOCK11. This anti-HBV agent contains, as an active ingredient, a substance which binds to DOCK11 and inhibits the function of DOCK11. In one embodiment, the anti-HBV according to th...
|
|
WO/2023/089544A1 |
The present invention relates to a pharmaceutical composition comprising an endolysin or an artilysin and an anti-cancer agent. In addition, the present invention relates to a pharmaceutical composition according to this invention for us...
|
|
WO/2023/090366A1 |
The present invention addresses the problem of providing an anticancer agent and/or a cardiac-function-improving agent having a novel action mechanism. A pharmaceutical composition containing, as an active ingredient, a substance that in...
|
|
WO/2023/088086A1 |
The present invention relates to a pair of tissue factors and an application thereof. The tissue factors are respectively TRIM31 and RHBDF2 which are derived from hepatic cells, and the TRIM31 and the RHBDF2 have a trade-off relationship...
|
|
WO/2023/085397A1 |
Provided is a detection method for Hunner-type interstitial cystitis diagnosis markers, the detection method detecting, from the urine of a subject, the presence amount of at least one microorganism selected from the group consisting of ...
|
|
WO/2023/082242A1 |
Provided in the present invention is the use of CTD-2256P15.2 and an encoding micropeptide thereof as a target in the development of a tumor treatment drug. Further provided in the present invention are the following uses of a CTD-2256P1...
|
|
WO/2023/086343A1 |
The present invention is directed to compositions comprising PLA2 inhibitors and optionally a metalloprotease inhibitor and/or an antivenom, antibody, antibody fragment or antibody derivative for topical, transdermal, buccal or sublingua...
|
|
WO/2023/083890A1 |
The invention relates to the use of compounds that reduce the signaling pathway induced by CLEC-1 /TRIM21 interaction, in particular compounds that antagonize the interaction, in particular the binding between CLEC-1 and TRIM21, the use ...
|
|
WO/2023/086927A1 |
Disclosed herein is a composition comprising a signal transducer and activator of transcription 3 (STAT3) inhibitor and one or more of a UNC51-like 1 (ULK1) inhibitor, histone deacetylase (HDAC) inhibitor, or an mTOR inhibitor in a pharm...
|
|
WO/2023/086796A2 |
Provided are methods for treating cancer by converting tumor-resident macrophages into a hybrid M1/M2 macrophage phenotype; this phenotype has attributes that are advantageous for cancer therapy. Hybrid markers include (lower than M2, hi...
|
|
WO/2023/083361A1 |
Disclosed is a new method for improving the quality of platelets. It is disclosed for the first time that the molecular of carnitine palmitoyl transferase II (CPT2) of the platelet mitochondrial inner membrane is critical to the survival...
|
|
WO/2023/086768A1 |
Disclosed herein are methods and compositions for inhibiting, preventing, ameliorating, reducing, or treating cardiovascular diseases, for example, stroke, traumatic brain injury, cerebral amyloid angiopathy, atherosclerosis, myocardial ...
|
|
WO/2023/083295A1 |
The present disclosure relates to ester derivatives of N 4-hydroxycytidine (NHC), to pharmaceutical compositions comprising thereof, to the preparation method thereof, and to the use and method of the ester derivatives of N 4-hydroxycyti...
|
